{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:44Z","timestamp":1781632364660,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In pulmonary tuberculosis (TB), smear positivity usually declines with effective treatment, but the time to non-infectiousness varies, creating uncertainty about the optimal duration of isolation. The Centers for Disease Control and Prevention (CDC) 2005 guidelines allow discharge before smear conversion to home isolation (restricted to healthcare visits until smear negativity) if no vulnerable household contacts are present, whereas hospitalized patients are advised to remain under airborne precautions until they have three consecutive negative smears. The practice in Qatar is to keep sputum smear positive TB patients in isolation facilities until smear negativity is achieved. Relying solely on smear conversion as a marker of non-infectiousness is problematic, as persistent smear positivity may reflect nonviable bacilli, or in some cases non-tuberculous mycobacteria, rather than ongoing transmission risk. This study evaluates the culture status of patients who remained smear-positive after two months of therapy to determine bacillary viability and reassess the validity of smear-based isolation practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to determine the proportion of culture-positive cases among pulmonary tuberculosis patients remaining smear-positive at two months of treatment and identify factors predictive of culture-negative status to support earlier isolation discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>A retrospective review of electronic medical records (2016\u20132024) was conducted at a tertiary TB center in Qatar, targeting patients smear-positive at two months. Data included demographics, disease extent (e.g. cavitary lesions), initial and two-month acid-fast bacilli (AFB) smear counts, two-month AFB cultures, drug resistance, and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 88 patients who remained smear-positive at two months of treatment. Among them, 61.4% were culture positive. Patients without cavitary lesions on the initial chest X-ray and those with two-month AFB counts\u2009&lt;\u200910\/100 fields had a 69% negative predictive value for culture negativity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over half of persistent smear-positive patients remain potentially infectious at two months. However, those without cavitary lesions and with low AFB counts in the two months smear could be candidates for earlier isolation discontinuation, optimizing resources and reducing patient burden. These findings support individualized isolation protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12173-x","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:53:39Z","timestamp":1769154819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of culture status in patients with persistent smear-positive pulmonary tuberculosis at two months of treatment"],"prefix":"10.1186","volume":"26","author":[{"given":"Junais","family":"Koleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraj S.","family":"Howady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P. N.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Al Balushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Al Maslamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"12173_CR1","unstructured":"World Health Organization. WHO guidelines on tuberculosis infection prevention and control: 2019 update [Internet]. Geneva: World Health Organization; 2019 [cited 2025 Feb 25]. Available from: https:\/\/iris.who.int\/handle\/10665\/311259."},{"issue":"RR-17","key":"12173_CR2","first-page":"1","volume":"54","author":"Centers for Disease Control and Prevention (CDC)","year":"2005","unstructured":"Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005 [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5417a1.htm.","journal-title":"MMWR Recomm Rep"},{"key":"12173_CR3","doi-asserted-by":"crossref","unstructured":"Cooper R, Williams M, Fennelly KP. Abandon the Acid-Fast Bacilli Smear for Patients With TB on Effective Treatment. Chest. 2023;164(1):21\u20133.","DOI":"10.1016\/j.chest.2023.02.006"},{"key":"12173_CR4","doi-asserted-by":"crossref","unstructured":"Nathavitharana RR, Pearl A, Biewer A, Young L, Mukasa L, Delrooz N, et al. Effects of respiratory isolation for tuberculosis to reduce community-based transmission: a systematic review. Clin Infect Dis. 2025;80(1):189\u201398.","DOI":"10.1093\/cid\/ciae496"},{"key":"12173_CR5","unstructured":"Forbes BA, Miller MB, Banaei N, Brown-Elliott BA, Das S, Salfinger M, et al. Laboratory detection and identification of mycobacteria."},{"key":"12173_CR6","unstructured":"Narvaiz de Kantor I, Kim SJ, Frieden TR, Laszlo A, Luelmo F, Norval PY, et al. Laboratory services in tuberculosis control. 1998 [cited 2025 Mar 4]; Available from: https:\/\/iris.who.int\/handle\/10665\/65942."},{"key":"12173_CR7","unstructured":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment [Internet]. [cited 2025 Mar 18]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240007048."},{"key":"12173_CR8","unstructured":"Qatar National Tuberculosis Program. National TB Control Pocket Guide, 4th Ed. Doha: MoPH and HMC; 2023."},{"key":"12173_CR9","doi-asserted-by":"crossref","unstructured":"Nader J, Albalushi S, Chaponda M, Howady F, Alsoub H, Hashim S, et al. Epidemiology of tuberculosis in Qatar: Eight-year retrospective cohort study [Internet]. In Review; 2024 [cited 2025 Jun 21]. Available from: https:\/\/www.researchsquare.com\/article\/rs-4942336\/v1.","DOI":"10.21203\/rs.3.rs-4942336\/v1"},{"key":"12173_CR10","doi-asserted-by":"crossref","unstructured":"Dharmadhikari AS, Mphahlele M, Venter K, Stoltz A, Mathebula R, Masotla T, et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2014;18(9):1019\u201325.","DOI":"10.5588\/ijtld.13.0834"},{"key":"12173_CR11","doi-asserted-by":"crossref","unstructured":"Shah M, Dansky Z, Nathavitharana R, Behm H, Brown S, Dov L, et al. National tuberculosis coalition of America (NTCA) Guidelines for respiratory isolation and restrictions to reduce transmission of Pulmonary Tuberculosis in Community Settings. Clin Infect Dis. 2024;ciae199.","DOI":"10.1093\/cid\/ciae199"},{"key":"12173_CR12","unstructured":"Riley RL. The contagiosity of tuberculosis. Schweiz Med Wochenschr. 1983;113(3):75\u20139."},{"key":"12173_CR13","doi-asserted-by":"crossref","unstructured":"Escombe AR, Moore DAJ, Gilman RH, Pan W, Navincopa M, Ticona E, et al. The infectiousness of tuberculosis patients coinfected with HIV. PLOS Med. 2008;5(9):e188.","DOI":"10.1371\/journal.pmed.0050188"},{"key":"12173_CR14","doi-asserted-by":"crossref","unstructured":"Nardell E a., Stoltz A, de Kock E, Nathavitharana R, Jensen P, Mendel C, et al. Measuring the early impact on transmission of new treatment regimens for drug resistant tuberculosis. In: C27 TB TREATMENT [Internet]. American Thoracic Society; 2019 [cited 2025 Feb 23]. p. A7387\u2013A7387. (American Thoracic Society International Conference Abstracts). Available from: https:\/\/www.atsjournals.org\/doi\/10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A7387.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A7387"},{"key":"12173_CR15","doi-asserted-by":"crossref","unstructured":"Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle. 1976;57(4):275\u201399.","DOI":"10.1016\/S0041-3879(76)80006-2"},{"key":"12173_CR16","doi-asserted-by":"crossref","unstructured":"Alhowady F, Elmaki N, Ali M, Husain A, Al-Maslamani M, Alsuwaidi Z, et al. 794. Infectivity of Smear-Positive Pulmonary TB After 2 Weeks of Rifampicin-based Anti-Tuberculous Therapy. Open Forum Infect Dis. 2018;5(Suppl 1):S285\u20136.","DOI":"10.1093\/ofid\/ofy210.801"},{"key":"12173_CR17","doi-asserted-by":"crossref","unstructured":"Goswami N, Reed C. Duration of effective tuberculosis treatment, not acid-fast bacilli (AFB) smear status, as the determinant for De-isolation in Community Settings. Clin Infect Dis. 2024;ciae198.","DOI":"10.1093\/cid\/ciae198"},{"key":"12173_CR18","unstructured":"Canada PHA of. Appendix B of the Canadian Tuberculosis Standards: de-isolation review and recommendations [Internet]. 2025 [cited 2025 Jun 21]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/tuberculosis\/health-professionals\/canadian-tuberculosis-standards\/appendix-b-de-isolation-review-recommendations.html."},{"key":"12173_CR19","doi-asserted-by":"crossref","unstructured":"Calderwood CJ, Wilson JP, Fielding KL, Harris RC, Karat AS, Mansukhani R, et al. Dynamics of sputum conversion during effective tuberculosis treatment: a systematic review and meta-analysis. PLoS Med. 2021;18(4):e1003566.","DOI":"10.1371\/journal.pmed.1003566"},{"key":"12173_CR20","doi-asserted-by":"crossref","unstructured":"Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest. 1999;116(3):726\u201331.","DOI":"10.1378\/chest.116.3.726"},{"key":"12173_CR21","doi-asserted-by":"crossref","unstructured":"Fennelly KP, Jones-L\u00f3pez EC, Ayakaka I, Kim S, Menyha H, Kirenga B, et al. Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2012;186(5):450\u20137.","DOI":"10.1164\/rccm.201203-0444OC"},{"key":"12173_CR22","doi-asserted-by":"crossref","unstructured":"Theron G, Limberis J, Venter R, Smith L, Pietersen E, Esmail A, et al. Bacterial and host determinants of cough aerosol culture-positivity in patients with drug-resistant versus drug-susceptible tuberculosis. Nat Med. 2020;26(9):1435\u201343.","DOI":"10.1038\/s41591-020-0940-2"},{"key":"12173_CR23","doi-asserted-by":"crossref","unstructured":"Nduba V, Njagi LN, Murithi W, Mwongera Z, Byers J, Logioia G, et al. Mycobacterium tuberculosis cough aerosol culture status associates with host characteristics and inflammatory profiles. Nat Commun. 2024;15(1):7604.","DOI":"10.1038\/s41467-024-52122-x"},{"key":"12173_CR24","doi-asserted-by":"crossref","unstructured":"Jones-L\u00f3pez EC, Kim S, Fregona G, Marques-Rodrigues P, Hadad DJ, Molina LPD, et al. Importance of Cough and M. tuberculosis Strain Type as Risks for Increased Transmission within Households. PLOS ONE. 2014;9(7):e100984.","DOI":"10.1371\/journal.pone.0100984"},{"key":"12173_CR25","doi-asserted-by":"crossref","unstructured":"Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, Moll A, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet Lond Engl. 2007;370(9597):1500\u20137.","DOI":"10.1016\/S0140-6736(07)61636-5"},{"key":"12173_CR26","doi-asserted-by":"crossref","unstructured":"Dinkele R, Gessner S, McKerry A, Leonard B, Leukes J, Seldon R, et al. Aerosolization of mycobacterium tuberculosis by Tidal Breathing. Am J Respir Crit Care Med. 2022;206(2):206\u201316.","DOI":"10.1164\/rccm.202110-2378OC"},{"key":"12173_CR27","doi-asserted-by":"crossref","unstructured":"Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. The Journal of Infectious Diseases. Oxford Academic [Internet]. [cited 2025 Feb 25]. Available from: https:\/\/academic.oup.com\/jid\/article\/212\/6\/990\/984852.","DOI":"10.1093\/infdis\/jiv149"},{"key":"12173_CR28","doi-asserted-by":"crossref","unstructured":"Shaikh A, Sriraman K, Vaswani S, Oswal V, Rao S, Mistry N. Early phase of effective treatment induces distinct transcriptional changes in Mycobacterium tuberculosis expelled by pulmonary tuberculosis patients. Sci Rep. 2021;11(1):17812.","DOI":"10.1038\/s41598-021-96902-7"},{"key":"12173_CR29","unstructured":"Kvach JT, Veras JR. A fluorescent staining procedure for determining the viability of mycobacterial cells. Int J Lepr Mycobact Dis Off Organ Int Lepr Assoc. 1982;50(2):183\u201392."},{"key":"12173_CR30","doi-asserted-by":"crossref","unstructured":"Van Deun A, Maug AKJ, Hossain A, Gumusboga M, de Jong BC. Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2012;16(9):1174\u20139.","DOI":"10.5588\/ijtld.11.0166"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12173-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:00:34Z","timestamp":1781629234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12173-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12173"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12173-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6430500\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study was approved by the Institutional Review Board, which is the ethical committee of Medical Research Center, Hamad medical corporation, Doha, Qatar. Patient Consent Statement is not applicable as there is no patient identifiable data. Exempted from written informed consent from study participants by the Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Institutional consent obtained for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}